Welcome to our dedicated page for Akebia Therapeutics SEC filings (Ticker: AKBA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Akebia Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Akebia Therapeutics's regulatory disclosures and financial reporting.
Akebia Therapeutics’ Chief Commercial Officer Nicholas Grund received new equity awards, aligning his compensation with company performance. On January 30, 2026, he was granted 204,000 shares of common stock as restricted stock units at $0.00 per share, bringing his directly owned common stock to 646,579 shares.
He was also granted a stock option for 320,000 shares of common stock at an exercise price of $1.41 per share, expiring on January 30, 2036. The RSUs vest in three equal annual installments, while the options vest over four years, both subject to his continued service.
Akebia Therapeutics disclosed that SVP and Chief Medical Officer Steven K. Burke received new equity awards on January 30, 2026. He was granted 204,000 restricted stock units of common stock at no cost and 320,000 stock options with a $1.41 exercise price.
The 204,000 restricted stock units vest in three equal installments on the first, second, and third anniversaries of the grant date, conditioned on continued service. The 320,000 options vest over four years, with 25% after one year and the remaining 75% in equal quarterly installments. Following the grant, Burke directly beneficially owns 1,016,090 shares of common stock, including 3,000 shares acquired through the company’s employee stock purchase plan.
Akebia Therapeutics SVP and Chief Legal Officer Carolyn M. Rucci reported new equity awards. On January 30, 2026, she received 190,000 shares of common stock in the form of restricted stock units at $0.00 per share, bringing her directly held common stock to 658,150 shares.
She was also granted a stock option for 270,000 shares of common stock with a $1.41 exercise price, all held directly. The restricted stock units vest in three equal annual installments, while the options vest over four years, both subject to continued service with the company.
Akebia Therapeutics reported an equity grant to SVP and Chief Accounting Officer Richard C. Malabre. On January 30, 2026, he received 79,000 restricted stock units and 119,000 stock options with a $1.41 exercise price, issued under Akebia’s 2023 Stock Incentive Plan.
The restricted stock units vest in three equal annual installments on the first, second and third anniversaries of the grant date, assuming continued service. The options vest over four years, with 25% vesting on the first anniversary and the remaining 75% vesting in equal quarterly installments. After this grant, Malabre beneficially owns 348,914 shares of common stock, including shares bought through the company’s employee stock purchase plan, and holds 119,000 stock options.
Akebia Therapeutics reported an equity compensation grant to its senior executive Erik Ostrowski, who serves as SVP, CFO, CBO and Treasurer. On January 30, 2026, he received 204,000 shares of common stock as restricted stock units at a price of $0.00 per share, bringing his directly held common stock to 707,586 shares.
He was also granted stock options covering 320,000 shares of common stock at an exercise price of $1.41 per share, expiring on January 30, 2036. One third of the restricted stock units vest on each of the first three anniversaries of the grant date, while 25% of the options vest on the first anniversary and the remaining 75% vest in equal quarterly installments over the following three years, in each case contingent on continued service.
Akebia Therapeutics CEO and President John P. Butler reported new equity awards on January 30, 2026. He received 743,000 shares of common stock as restricted stock units at a price of $0.00 per share, bringing his directly held common stock to 3,463,849 shares.
He was also granted a stock option for 1,115,000 shares at an exercise price of $1.41 per share, expiring on 01/30/2036. These options vest over four years, while the restricted stock units vest in three equal annual installments, both subject to his continued service. An additional 159,928 shares are held indirectly through the Dorothy Butler Revocable Trust.
Akebia Therapeutics executive Carolyn M. Rucci, SVP and Chief Legal Officer, filed an initial ownership report showing her equity position in the company. She reports beneficial ownership of multiple blocks of Akebia common stock, including 171,816 shares held directly and additional shares linked to restricted stock unit grants.
The filing also lists several employee stock options to buy Akebia common stock, with exercise prices ranging from $0.63 to $2.88 per share and expiration dates between 2031 and 2035. These options generally vest over four years, with 25% vesting after one year and the remainder in equal quarterly installments, subject to continued service.
A shareholder of Akebia Therapeutics, Inc. has filed a notice of proposed sale of 34951 shares of common stock through Morgan Stanley Smith Barney LLC on the Nasdaq. The filing lists an aggregate market value of 48739.00 for these shares.
The shares are part of a much larger base of 265365993 shares outstanding. They were acquired as restricted stock on 01/31/2026, with a listed payment date of 02/02/2026. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information about the issuer.
Akebia Therapeutics, Inc. shareholder plans to sell common stock under Rule 144. The notice covers the proposed sale of 84,829 shares of Akebia common stock, with an aggregate market value of $118,294.00. The shares are to be sold through Morgan Stanley Smith Barney LLC on the Nasdaq market, with an approximate sale date of February 2, 2026.
The securities were acquired as restricted stock from Akebia Therapeutics, Inc. on January 31, 2026, with 84,829 shares granted and payment noted as non-cash. The filing also notes total shares outstanding of 265,365,993 common shares, providing context for the size of the proposed sale.
A shareholder of Akebia Therapeutics, Inc. filed a Rule 144 notice to sell 67,658 shares of common stock on the Nasdaq through Morgan Stanley Smith Barney LLC, for an aggregate market value of $94,349. These shares were acquired as restricted stock from Akebia on January 31, 2026, with payment dated February 2, 2026. The filing notes that 265,365,993 shares of the issuer’s common stock are outstanding.